NCT06410066

Brief Summary

The investigators sought to report the outcomes of patients with haematological malignancies admitted to the intensive care units and to define pre-intensive care units prognostic factors for in-hospital all-cause mortality. In this retrospective, single-center study, all patients with haematologic malignancies admitted to intensive care units between 2009 and 2019 were included. The primary outcome was in-hospital mortality.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
144

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2009

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2009

Completed
11 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2019

Completed
2.1 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 20, 2022

Completed
2.3 years until next milestone

First Submitted

Initial submission to the registry

May 2, 2024

Completed
8 days until next milestone

First Posted

Study publicly available on registry

May 10, 2024

Completed
Last Updated

May 10, 2024

Status Verified

May 1, 2024

Enrollment Period

11 years

First QC Date

May 2, 2024

Last Update Submit

May 8, 2024

Conditions

Hematologic Malignancy

Keywords

intensive care unithaematologic malignancymortality

Outcome Measures

Primary Outcomes (1)

  • mortality

    in hospital mortality

    30 day

Study Arms (1)

PATIENTS WITH HEMATOLOGIC MALIGNANCY aADMITTED TO THE ICU

all consecutive patients diagnosed with HM and admitted to both ICUs between January 2009 and December 2019.

Other: no intervention

Interventions

no interventionOTHER
PATIENTS WITH HEMATOLOGIC MALIGNANCY aADMITTED TO THE ICU

Eligibility Criteria

Age18 Years - 100 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all consecutive patients diagnosed with HM and admitted to both ICUs between January 2009 and December 2019.

You may qualify if:

  • diagnosis of HM on admission or discharge from the ICU

You may not qualify if:

  • patients under 18 years of age patients who were completely cured of malignancy for more than five years patients admitted to the ICU during the COVID-19 pandemic

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Hematologic Neoplasms

Condition Hierarchy (Ancestors)

Neoplasms by SiteNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
OTHER
Target Duration
30 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
senior physician, head of ECMO service SUMC

Study Record Dates

First Submitted

May 2, 2024

First Posted

May 10, 2024

Study Start

January 1, 2009

Primary Completion

December 31, 2019

Study Completion

January 20, 2022

Last Updated

May 10, 2024

Record last verified: 2024-05

Data Sharing

IPD Sharing
Will not share